Aigen Investment Management LP Has $373,000 Stock Holdings in RxSight, Inc. (NASDAQ:RXST)

Aigen Investment Management LP lessened its holdings in RxSight, Inc. (NASDAQ:RXST) by 53.9% during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 9,261 shares of the company’s stock after selling 10,837 shares during the quarter. Aigen Investment Management LP’s holdings in RxSight were worth $373,000 as of its most recent SEC filing.

A number of other large investors have also recently modified their holdings of RXST. RiverPark Advisors LLC lifted its position in shares of RxSight by 70.0% during the 4th quarter. RiverPark Advisors LLC now owns 668 shares of the company’s stock worth $27,000 after buying an additional 275 shares during the last quarter. Amalgamated Bank grew its holdings in shares of RxSight by 7.7% during the 4th quarter. Amalgamated Bank now owns 4,148 shares of the company’s stock valued at $167,000 after purchasing an additional 298 shares during the last quarter. Clarus Group Inc. bought a new position in RxSight in the 4th quarter valued at approximately $202,000. Thompson Davis & CO. Inc. bought a new position in RxSight in the 4th quarter valued at approximately $212,000. Finally, Penn Mutual Asset Management LLC acquired a new stake in RxSight in the third quarter valued at approximately $230,000. Institutional investors and hedge funds own 78.78% of the company’s stock.

RxSight Stock Performance

Shares of NASDAQ RXST traded up $0.56 during midday trading on Friday, reaching $61.15. The stock had a trading volume of 309,541 shares, compared to its average volume of 501,330. The company’s 50 day moving average price is $55.26 and its 200 day moving average price is $46.78. RxSight, Inc. has a twelve month low of $20.66 and a twelve month high of $66.54. The firm has a market cap of $2.26 billion, a price-to-earnings ratio of -48.53 and a beta of 1.21.

RxSight (NASDAQ:RXST) last released its earnings results on Monday, May 6th. The company reported ($0.25) EPS for the quarter, missing the consensus estimate of ($0.17) by ($0.08). RxSight had a negative return on equity of 27.68% and a negative net margin of 44.01%. The business had revenue of $29.51 million for the quarter, compared to analyst estimates of $27.56 million. During the same period in the prior year, the business earned ($0.42) EPS. The company’s revenue for the quarter was up 68.7% on a year-over-year basis. Equities analysts forecast that RxSight, Inc. will post -0.78 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of research analysts have recently commented on RXST shares. BTIG Research increased their price target on RxSight from $61.00 to $72.00 and gave the company a “buy” rating in a research note on Tuesday, May 7th. JPMorgan Chase & Co. lifted their price target on RxSight from $40.00 to $62.00 and gave the company an “overweight” rating in a research note on Thursday, February 29th. Wells Fargo & Company upped their price objective on RxSight from $61.00 to $68.00 and gave the company an “overweight” rating in a research note on Tuesday, May 7th. Needham & Company LLC lifted their target price on shares of RxSight from $64.00 to $75.00 and gave the stock a “buy” rating in a research report on Tuesday, May 7th. Finally, Oppenheimer upped their price target on shares of RxSight from $61.00 to $72.00 and gave the company an “outperform” rating in a research report on Tuesday, May 7th. Seven investment analysts have rated the stock with a buy rating, According to MarketBeat, the stock has an average rating of “Buy” and a consensus price target of $60.63.

Insider Transactions at RxSight

In related news, CFO Shelley B. Thunen sold 20,000 shares of the firm’s stock in a transaction dated Monday, April 1st. The shares were sold at an average price of $49.90, for a total value of $998,000.00. Following the transaction, the chief financial officer now owns 8,402 shares of the company’s stock, valued at approximately $419,259.80. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. In other RxSight news, CEO Ronald M. Md Kurtz sold 40,000 shares of the stock in a transaction dated Friday, May 3rd. The shares were sold at an average price of $60.15, for a total value of $2,406,000.00. Following the completion of the sale, the chief executive officer now owns 764,610 shares in the company, valued at approximately $45,991,291.50. The transaction was disclosed in a document filed with the SEC, which is available at this link. Also, CFO Shelley B. Thunen sold 20,000 shares of RxSight stock in a transaction that occurred on Monday, April 1st. The stock was sold at an average price of $49.90, for a total transaction of $998,000.00. Following the transaction, the chief financial officer now directly owns 8,402 shares in the company, valued at approximately $419,259.80. The disclosure for this sale can be found here. Insiders have sold 80,000 shares of company stock valued at $4,494,600 over the last ninety days. 21.13% of the stock is owned by company insiders.

About RxSight

RxSight, Inc, a commercial-stage medical device company, engages in the research and development, manufacture, and sale of light adjustable intraocular lenses (LAL) used in cataract surgery in the United States and internationally. It offers RxSight system that enables doctors to customize and enhance the visual acuity for patients after cataract surgery.